Dr Brewer

Have pharmacy sent treatment try with nosoneb

Dr. Brewer is an ME/CFS specialist in Kansas City. He is one of the good ones, because he listens to his patients and learns from them. He is always on the lookout for the latest treatment that might help his patients. For example, he was one of the first doctors to prescribe Rich Van Konynenberg's simplified methylation protocol.

Apparently a few years ago Dr. Brewer became aware of the patients and doctors who have been saying that they think mycotoxins are involved somehow in ME/CFS. He started asking his patients if they had ever been exposed to a moldy building. He was surprised how many said yes. So he decided to test a group of his patients for mycotoxins in their urine.

Of the group he tested, almost all of them had enough mycotoxins in their urine to register as positive on the test. There were only a few people who were negative. They were not excreting enough mycotoxins to be unusual. Later on he figured out that most of those few people were just really slow detoxers.

He came up with a theory. What if people with ME/CFS have an internal source of mycotoxins? Where in the human body could toxin-producing fungi be hanging out? What if it is living in a bioflim in the sinuses? (a biofilm is like a protective layer of crud)

So he gathered a group of his patients who wanted to be his guinea pigs and who were sure that they were not currently living in a moldy home. You shouldn't do this protocol if you are currently living in a place with a mold issue. He started out by prescribing them three things:

A NasaTouch machine
an antifungal drug (Amphotericin-B or Nystatin)
a chelating agent

A NasaTouch machine is an aerosolizer. It delivers medicine deep into the sinuses. At first he had his patients use the NasaTouch machine to administer a dose of the chelating prescription every morning and a dose of the Ampho-B every evening. The chelating prescription breaks up the biofilm, which has metals in it. Sure enough, it worked. Some people began to feel better in terms of their ME/CFS symptoms.

But right from the beginning he has been tweaking this protocol, using feedback from patients. Ampho-B is a really strong drug, and it can produce intolerable side effects. So he had his patients experiment with taking it every other day, or taking a half-dose of it.

Eventually he tried prescribing his patients Nystatin instead of Ampho-B. They are both drugs that are made out of bacteria which kill fungi. But Nystatin is much easier to tolerate. Again he let his more sensitive patients experiment with taking it less often, or in smaller doses.

When you send bacteria up into your sinuses to kill fungi, it starts a war. Fungi release toxins as they are killed. So the limiting factor of this treatment is how fast a patient can detox the garbage it produces. You can only do it as fast as you can detox.

So Dr. Brewer has been suggesting that his patients use a Far-Infrared Sauna to help them detox more through the skin. He has been using folate and B-12 to help patients detox faster.

In general, his published papers are lagging behind what he is doing currently with his patients. At first he had some patients who felt completely well after a year or two of treatment. But now he is realizing that it is going to take some people longer than that. And now he is saying that maybe the chelating agent is not neccessary for some people. And now he is saying that he thinks Nystatin is just as effective as Ampho-B. It keeps evolving.

You don't have to be a patient of Dr. Brewer to do his protocol. All you have to do is find a doctor who will prescribe you the three things from the Imprimis Pharmacy. (It used to be called the TAG pharmacy) He prescribes 50,000 IU capsules of Nystatin. You will have to ask the pharmacy about the chelating prescription. I'm not sure what the dosage of that is or what it is officially called.

When you take a dose of Nystatin, you do this: Mix up some saline solution. Open the capsule and dissolve the contents in 5 ml of saline solution. Put it in the NasaTouch machine and administer it. Wash the NasaTouch parts that are washable.

Antimycotics

Itraconozole. Consider increasing dosage or adding adjunct azole antimycotic agents such as clotrimazole (Canesten), econazole. miconazole or Voriconazole, ravuconazole, and posaconazole, three new azole drugs that have been developed and may be of use in both systemic and superficial fungal infections. Or adjunct antimycotics from a different class such as the polyenes, allylamines and echinocandins. A test to check the effect of Itraconozole and antimycotic agents on liver check (combined with the prescriptions taking including Venlafaxin, Prazosin, Propranolol plus any other proposed antimycotics that may be introduced, nasal or otherwise

1b) antimycotics required reading IntranasalAntifungalTherapy https://drive.google.com/file/d/1E6FuHqV1nC_-u7O7ILeegvf-rEwCI77Y/view?usp=sharing

Intranasal Antifungal Therapy Article Highlights click arrow to open

Exposure to mycotoxin producing mold and mycotoxins can be associated with numerous adverse health consequences. We previously reported that patients with chronic illness frequently had a history of prior exposure to water damaged buildings (WDB) and mold. Additionally, the vast majority of these patients had mycotoxins present in the urine. We have postulated that the mycotoxin producing molds were likely harbored internally in the sinuses of these patients. In the present analysis, patients with chronic illness and a positive urine mycotoxin assay were treated with intranasal antifungal therapy, either amphotericin B (AMB) or itraconazole (ITR). AMB was associated with local (nasal) irritation adverse effects (AE) in 34% of the cases, which resulted in discontinuation. In patients that remained on therapy without AE, we found that 94% improved clinically. Additionally, we found that the urine mycotoxin levels decreased substantially in patients that improved on therapy. Similar findings were seen with ITR, however the number of patients treated was much smaller

Using a sensitive and specific assay developed by RealTime Laboratories (RTL), we recently published a study linking the presence of aflatoxins (AT), ochratoxin A (OT) and/or macrocyclic trichothecenes (MT) to chronic fatigue syndrome (CFS) [4]. A significant number of these chronically ill patients were ill for many years, with average illness duration of more than seven years (range 2–36). Furthermore, over 90% of the patients gave a history of exposure to a WDB, mold or both. Exposure histories often indicated the WDB exposure occurred many years prior to the mycotoxin testing and furthermore, many of these patients did not report recent or current exposure to a WDB or moldy environment. Despite the remote history of exposure, these patients remained chronically ill and demonstrated the presence of significantly elevated concentrations of mycotoxins on urine testing. The persistence of illness years after exposure as well as the presence of mycotoxins suggested that there might be internal mold that represented a reservoir for ongoing internal mycotoxin production, either continuous or intermittent. Recently we described the concept that the nose and sinuses may be the major internal reservoirs where the mold is harbored in biofilm communities [5]. This presence of mold can lead to the generation of mycotoxins internally. Thus, treatments aimed at reduction or elimination of the mold/fungi in the paranasal sinuses could lead to clinical improvement and in these patients. Herein, we present and discuss our observations in chronically ill patients who were treated with intranasal antifungal therapy

Additionally, the study observed that seven patients who had shown clinical improvement decided to discontinue therapy. Out of these seven patients, six were from the AMB group, while one was receiving ITR. The most common reason given for discontinuation was the belief that the patients were "cured." During the course of therapy, these patients had their mycotoxin levels measured and then again after discontinuing therapy. The data regarding relapses and the results of repeat mycotoxin levels are not provided.

The study also indicates that the optimal choice of antifungal agent, appropriate dosage, dosing frequency, most effective administration method, and duration of therapy have not been fully determined. Due to the frequent adverse effects experienced locally with AMB, alternative antifungal agents should be considered. ITR is one such option; however, concerns exist regarding its potential for systemic absorption, as mentioned previously.

Another potential option is intranasal nystatin. Although nystatin has traditionally been used topically for yeast infections, it has demonstrated good activity against molds in laboratory studies. Since nystatin is classified as a polyene antifungal agent, similar to AMB, it is expected to have comparable effects. It is anticipated that nasal irritation may be less common with nystatin, and moreover, it does not get systemically absorbed, boasting a well-established clinical safety profile. It is worth noting that intranasal nystatin was not available during the conducted study but may be a viable option worth pursuing.

Furthermore, there is interest in exploring alternative agents capable of disrupting biofilms. In this context, mupirocin has been studied as a therapy for chronic rhinosinusitis (CRS) patients and has exhibited effectiveness. Additionally, mupirocin has shown activity against biofilm formation.

However, further research is needed to establish the most appropriate treatment agent, optimal dosage and frequency, best administration method, and duration of therapy. Additionally, the potential systemic effects of certain antifungal agents, such as ITR, should be considered. Alternative options, such as intranasal nystatin and agents targeting biofilms like mupirocin, show promise but require further investigation.

1c) See candida alzheimers link https://www.genengnews.com/news/candida-albicans-produces-alzheimers-like-changes-in-the-brain/#:~:text=Now researchers have uncovered how,at the center of the

1e) IntraNasal antimycotic therapies click arrow to open

dr brewer protocol

Dr. Joseph Brewer's Protocol is a multi-step treatment that aims to remove mycotoxins and colonized mold from the nasal cavity. The protocol involves using a topical antifungal and a chelating agent.

Brewer's Protocol aims to improve health by preventing frequent nasal passage infections. He has a long-standing interest in chronic illness patients, including chronic fatigue syndrome (CFS) and Lyme disease, In 2019, he shared a study report that found a high percentage of CFS patients have mycotoxins in their urine.

Mold can form in buildings with leaks and water damage. When mold forms, it releases toxic bacteria and substances that can be inhaled. These bacteria can then colonize in the nasal passages

Brewer’s Protocol - Forte Rx Compounding Pharmacy https://forterx.com/brewers-protocol

*Dr. Brewer’s Protocol Brewer’s Protocol is a multi-step biofilm-focused treatment for mycotoxins involving the use of a topical antifungal and a chelating agent. Dr. Joseph Brewer is an infectious disease specialist in private practice from Kansas City, Missouri. Dr. Brewer has a special interest in biotoxin illnesses/mold toxicity, Fibromyalgia, Chronic Fatigue Syndrome (CFS), Lyme Disease, and HIV/AIDS and has published ground-breaking papers like “Detection of mycotoxins in patients with Chronic Fatigue Syndrome”* and “Chronic illness associated with mold and mycotoxins: is naso-sinus fungal biofilm the culprit?”. Dr. Brewer and his colleagues have made important discoveries in the treatment protocols of mold-exposed patients. Dr. Brewer’s publications have exposed an important link between mold exposure and chronic illnesses such as chronic fatigue syndrome (CFS) and fibromyalgia. [58] Furthermore, he has shown that the sinus area is a major internal reservoir that harbors mold in biofilm communities that generate mycotoxins internally.[59] Biofilm provides considerable protection for fungi, allowing them to chronically persist within the sinuses.[60] Recognizing this new information has enabled us to improve our treatment for mold toxicity and biotoxin illness. Dr. Brewer’s research concludes that an effective protocol for mold-exposed patients must target fungal biofilm in the sinuses. [61] This includes the use of a chelating agent, such as EDTA, to disrupt biofilm as well as intranasal antifungal therapy with antifungal agents like Amphotericin B or Nystatin.[62] In addition, Bactroban (mupirocin) is often recommended to be used alongside the antifungal and chelating agent to aid in biofilm disruption. [63]Topical antibiotics have been widely used in the treatment of biofilm due to their easy administration and minimal systemic adverse effects.[64] In a clinical trial on the efficacy of topical Bactroban (mupirocin) treatment in the sinuses of chronic sinusitis (CRS) patients, it was concluded that mupirocin could be useful in eliminating Staphylococcus aureus (S. aureus) biofilms present on the sinus mucosa of CRS patients and offer an additional treatment method for patients with recurring sinusitis.[65]

At Forte Rx Compounding Pharmacy, we offer the complete Brewer’s protocol which includes the Rhino Clear Atomizer, EDTA solution, antifungals Amphotericin B solution and Nystatin as well as Bactroban (mupirocin) solution

Joseph Brewer MEpedia https://me-pedia.org/wiki/Joseph_Brewer

61 Allopathic Medicine https://cfshelp.info/61-allopathic-medicine.html

This protocol involves patients taking either a nasal version of Amphotericin B or a compounded Nystatin that has to be atomised. Patients should also take a chelating PX. A pilot study by Dr. Brewer found that 56 out of 151 ME/CFS patients could not tolerate the Amphotericin B. 88 out of the remaining 94 patients (93.6%) had a reduction in symptoms. Approximately a third of these 88 CFS patients reached remission. Since this pilot study, Dr. Brewer has used a compounded and atomised Nystatin due to it being safer than the nasal Amphotericin B. The theory behind Dr. Brewer’s Protocol involves treating the sinus reservoirs of mycotoxins that may be causing ME/CFS symptoms. Since replacing Amphotericin B with Nystatin, Dr. Brewer’s Protocol has become safer for patients, with followers of the protocol rarely reporting nasal side effects. Patients experiencing die-off symptoms range from 30-40% according to Dr. Brewer. The appropriate dosages of the compounded and atomised Nystatin and the chelating PX are provided by the compounding pharmacy

Intranasal Nystatin Therapy: Intranasal Nystatin therapy is a specific form of intranasal antifungal therapy used to address naso-sinus colonization with toxic molds and mycotoxins in patients with chronic illnesses

intranasal antifungal therapy in patients with medicalresearchjournal.org - Google Search https://www.google.com/search?q=intranasal+antifungal+therapy+in+patients+with+medicalresearchjournal.org&rlz=1C1CHBF_enUS1029US1029&oq=intranasal+antifungal+therapy+in+patients+with+medicalresearchjournal.org&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIGCAEQRRhB0gEJNDI3NDhqMGo3qAIAsAIA&sourceid=chrome&ie=UTF-8#ip=1

View of Intranasal Antifungal Therapy in Patients with Chronic Illness Associated with Mold and Mycotoxins: An Observational Analysis https://medicalresearchjournal.org/index.php/GJMR/article/view/925/835

View of Intranasal Nystatin Therapy in Patients with Chronic Illness Associated with Mold and Mycotoxins | Global Journal of Medical Research https://medicalresearchjournal.org/index.php/GJMR/article/view/1037/6-Intranasal-Nystatin-Therapy_html

Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis - Journal of Allergy and Clinical Immunology https://www.jacionline.org/article/S0091-6749(02)01467-7/fulltext

Intranasal Nystatin Therapy in Patients with Chronic Illness Associated with Mold and Mycotoxins - LaTeX+pdf+Kaleidoscope*+(Beta+by+AI).pdf chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://medicalresearchjournal.org/index.php/GJMR/article/download/1037/6-Intranasal-Nystatin-Therapy_LaTeX_pdf/30871

Topical Antibiofilm Agents With Potential Utility in the Treatment of Chronic Rhinosinusitis: A Narrative Review

1e2) other antimycotics therapies click arrow to open

anti candida - Google Search https://www.google.com/search?q=anti+candida&rlz=1C1CHBF_enUS1029US1029&oq=anti&gs_lcrp=EgZjaHJvbWUqBggBEEUYOzIGCAAQRRg5MgYIARBFGDsyBggCEEUYPDIGCAMQRRg9MgYIBBBFGDwyBggFEEUYQTIGCAYQRRhBMgYIBxBFGEHSAQkyMDYzMWowajeoAgCwAgA&sourceid=chrome&ie=UTF-8

anti mold in stomach - Google Search https://www.google.com/search?q=anti+mold+in+stomach&rlz=1C1CHBF_enUS1029US1029&oq=anti+mold+in+stomach&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBCDY0MTZqMGo3qAIAsAIA&sourceid=chrome&ie=UTF-8

myocardial peptide antibodies - Google Search https://www.google.com/search?q=myocardial+peptide+antibodies&rlz=1C1TSNO_enUS609US609&oq=myocardial+peptide+antibodies&aqs=chrome..69i57&sourceid=chrome&ie=UTF-8#q=myocardial+peptide+antibodies+chronic+fatigue